ACR & Coalition Letters to Federal Policymakers

Rheumatology advocacy involves several branches of government and various agencies. ACR advocates to Congress, federal agencies, and others by writing or signing on to various policy letters.

2018 Federal Advocacy Letters

Coalition Letter on Medicare Advantage Step Therapy - 10/1/18

ACR Response to CMS on Competitive Acquisition Program Request for Information - 9/24/18

ACR Letter to CMS on 2019 Physician Fee Schedule and Quality Payment Program - 9/6/18

ACR Comments in FDA Public Meeting on Biosimilars - 9/5/18

Stakeholder Letter to CMS on E/M Proposals in 2019 Medicare Physician Fee Schedule - 8/28/18

ACR Letter to HHS on Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs - 7/13/18

Coalition Letter to CMS on Shortening the 2018 MIPS Reporting Period - 4/27/18

ACR Letter to CMS on Short-Term Limited Duration Insurance - 4/23/18

Coalition Letter to CMS on Short-Term Limited Duration Insurance - 4/23/18

Coalition Letter to CMS on Prior Authorization under Medicare Advantage and the Patients Over Paperwork Initiative - 4/4/18

Physician Group Letter to HHS on Drug Pricing Proposals - 3/14/18

ACR Comments to CMS on Clinical Laboratory Improvement Amendments - 3/12/18

ACR Comments to Department of Labor on Association Health Plan Proposed Rule - 3/5/18

ACR Response to HHS Request for Information on Promoting Healthcare Choice and Competition - 1/25/18

ACR Letter to FDA: Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases - 1/19/18

Coalition Letter to House on MIPS Adjustment to Part B Drugs - 1/18/18

Coalition Letter to Senate on MIPS Adjustment to Part B Drugs - 1/18/18

ACR Letter to CMS on Medicare Advantage Proposed Rule - 1/16/18